RELAPSING MULTIPLE SCLEROSIS

This study will follow 2000 people with relapsing multiple sclerosis who are prescribed BRIUMVI, a medication given by infusion. Researchers want to see how well the drug works in everyday life and track any side effects. Participants must not have received BRIUMVI before and can…

This study tests a modified dosing schedule of ublituximab, a drug that targets certain immune cells, in 800 people with relapsing multiple sclerosis (MS). The goal is to see if the new regimen reduces brain lesions better than current approaches. Participants include those new t…

This study compares a stem cell transplant (AHSCT) to the best standard treatments for people with relapsing multiple sclerosis that hasn't responded to other therapies. About 156 participants will be randomly assigned to one of the two groups and followed for six years. The goal…

This study tests whether a new drug called CYB704 works as well as the approved MS treatment Ocrevus. About 175 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare how the drug spreads in the body, its effects on MS brain lesio…

This study looks at whether people with stable relapsing multiple sclerosis (MS) can safely switch from a strong infusion therapy (anti-CD20) to a daily pill (ozanimod). The goal is to see if the pill can keep the disease under control with fewer serious infections. About 100 adu…

This study is testing the drug ocrelizumab in 60 Chinese adults with relapsing or primary progressive multiple sclerosis (MS). The goal is to see how well it controls relapses and reduces immune cells linked to MS. Participants receive the drug by infusion, and researchers monito…

This study tests whether a new drug called remibrutinib works as well as the current drug ocrelizumab for people with relapsing multiple sclerosis. About 360 adults aged 40-70 who are already on ocrelizumab will either switch to remibrutinib or stay on ocrelizumab. The goal is to…

This early-stage study tests a new cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis (MS) who still experience disease activity despite taking strong MS medications. The goal is to see if YTB323 is safe and can help control the disease. Participants …

This study tests an experimental drug called fenebrutinib in 12 children and teens (ages 10 to under 18) with relapsing multiple sclerosis. The goal is to see how the drug works in the body, whether it reduces brain lesions, and if it is safe. Participants can choose to continue …

This study tests if a shot (subcutaneous) of the drug ublituximab works as well as the standard IV version for people with relapsing multiple sclerosis. About 360 adults with MS will receive either the shot or the IV, and researchers will measure drug levels in the blood and moni…

This study follows 800 adults in Germany with relapsing multiple sclerosis to see how long they continue their prescribed injectable or oral medications. Researchers will collect information from medical records and questionnaires over up to four years. The goal is to understand …

This study looks at how much of the multiple sclerosis drug BRIUMVI passes into breast milk. About 16 women with relapsing MS who are already taking BRIUMVI and choose to breastfeed will provide milk samples. The goal is to measure drug levels, not to treat or cure the disease.